Questions about COVID-19 associated coagulopathy: possible answers from the viscoelastic tests.

Pavoni, Vittorio; Gianesello, Lara; Pazzi, Maddalena; Dattolo, Pietro; Prisco, Domenico

Abnormal coagulation parameters are often observed in patients with coronavirus disease 2019 (COVID-19) and the severity of derangement has been associated with a poor prognosis. The COVID-19 associated coagulopathy (CAC) displays unique features that include a high risk of developing thromboembolic complications. Viscoelastic tests (VETs), such as thromboelastometry (ROTEM), thromboelastography (TEG) and Quantra Hemostasis Analyzer (Quantra), provide "dynamic" data on clot formation and dissolution; they are used in different critical care settings, both in hemorrhagic and in thrombotic conditions. In patients with severe COVID-19 infection VETs can supply to clinicians more information about the CAC, identifying the presence of hypercoagulable and hypofibrinolysis states. In the last year, many studies have proposed to explain the underlying characteristics of CAC; however, there remain many unanswered questions. We tried to address some of the important queries about CAC through VETs analysis.

COVID-19 pandemic; THROMBELASTOGRAPHY; HEMOSTASIS; DISEASES; THROMBOSIS

Journal of Clinical Monitoring & Computing, 2022, Vol 36, Issue 1, p55

1387-1307

Academic Journal

10.1007/s10877-021-00744-7